GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Connect Biopharma Holdings Ltd (NAS:CNTB) » Definitions » Interest Coverage

Connect Biopharma Holdings (Connect Biopharma Holdings) Interest Coverage : 0 (At Loss) (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Connect Biopharma Holdings Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Connect Biopharma Holdings's Operating Income for the six months ended in Dec. 2023 was $-32.94 Mil. Connect Biopharma Holdings's Interest Expense for the six months ended in Dec. 2023 was $-0.01 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Connect Biopharma Holdings's Interest Coverage or its related term are showing as below:


CNTB's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 137.02
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Connect Biopharma Holdings Interest Coverage Historical Data

The historical data trend for Connect Biopharma Holdings's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Connect Biopharma Holdings Interest Coverage Chart

Connect Biopharma Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
- - - - -

Connect Biopharma Holdings Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Interest Coverage Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Connect Biopharma Holdings's Interest Coverage

For the Biotechnology subindustry, Connect Biopharma Holdings's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Connect Biopharma Holdings's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Connect Biopharma Holdings's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Connect Biopharma Holdings's Interest Coverage falls into.



Connect Biopharma Holdings Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Connect Biopharma Holdings's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Connect Biopharma Holdings's Interest Expense was $-0.02 Mil. Its Operating Income was $-64.85 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.18 Mil.

Connect Biopharma Holdings did not have earnings to cover the interest expense.

Connect Biopharma Holdings's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the six months ended in Dec. 2023, Connect Biopharma Holdings's Interest Expense was $-0.01 Mil. Its Operating Income was $-32.94 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.18 Mil.

Connect Biopharma Holdings did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Connect Biopharma Holdings  (NAS:CNTB) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Connect Biopharma Holdings Interest Coverage Related Terms

Thank you for viewing the detailed overview of Connect Biopharma Holdings's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Connect Biopharma Holdings (Connect Biopharma Holdings) Business Description

Traded in Other Exchanges
N/A
Address
12265 El Camino Real, Suite 350, San Diego, CA, USA, 92130
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.

Connect Biopharma Holdings (Connect Biopharma Holdings) Headlines

From GuruFocus

Connect Biopharma to Participate at the Jefferies Healthcare Conference

By GuruFocusNews GuruFocusNews 06-22-2022